All doses of the diabetes and weight management injectable tirzepatide (Mounjaro, Zepbound) were taken off the FDA's shortage ...

In this randomized controlled trial, in patients with both moderate-severe obstructive sleep apnea (OSA) and obesity, it was ...

Mounjaro, the brand name for tirzepatide, is a drug that treats type 2 diabetes by lowering blood sugar levels. According to ...

Some patients fear that they’ll lose access to tirzepatide because the US Food and Drug Administration determined that a ...

There’s a war brewing over blockbuster weight loss medications — and patients are now getting caught in the crossfire.

These drugs work similarly but differ in dosage and specific indications (uses). Research suggests that tirzepatide is more ...

Now that the Mounjaro and Zepbound shortage is over, Eli Lilly is going after the cottage industry selling “compounded” ...

Poor purity can cause patients to experience fever, chills, nausea, skin irritation, infections and low blood pressure.

Mounjaro and Zepbound are now out of shortage. This should be good news—but because so many patients are taking compounded ...

On October 3, 2024, the US Food and Drug Administration (FDA) revised its shortage categorization of tirzepatide, a glucagon-like peptide 1 ...

With the resolution, compounding pharmacies are no longer able to produce tirzepatide. And the FDA highlighted the point to ...

With an estimated 2 million people in the United States taking copycat vers | A compounding industry group has sued the FDA, ...